Last updated: February 14, 2026
What is the Product and Its Current Market Position?
NDC 00093-8192 corresponds to Tivicay (dolutegravir), an antiretroviral medication used in the treatment of HIV-1 infection. Dolutegravir is an integrase strand transfer inhibitor (INSTI), part of a widely prescribed class for HIV management.
Market Share:
Tivicay holds a significant share of the antiretroviral (ARV) market, especially within combination therapies like Triumeq and Juluca. Its efficacy, safety profile, and resistance barrier contribute to high formulary adoption. As of 2022, Tivicay captures approximately 40% of the baseline INSTI segment [1].
Regulatory Status:
Approved by FDA in 2013, Tivicay was the first to introduce once-daily dosing with a high barrier to resistance. It has received extensions for pediatric use and fixed-dose combinations.
How Large Is the Market?
Global HIV Market (2023):
- Estimated revenue: $22 billion.
- Projected CAGR (2022-2027): 2.8%.
- Main markets: US, Europe, Japan, Canada, Australia.
US Market Share (2022):
- The US accounts for approximately 45% of global ARV sales, driven by high diagnosis and treatment rates.
- Dolutegravir-based regimens dominate newer ART options, with sales reaching nearly $2.9 billion in the US in 2022 [2].
Patient Population:
- Estimated 1.2 million adults living with HIV in the US, with annual treatment initiation around 20,000–25,000 patients.
- US treatment coverage exceeds 85%, indicating stable demand for continued therapy options like Tivicay.
Competitive Landscape
Major Competitors:
- Bictegravir (Biktarvy) (Gilead)
- Raltegravir (Isentress) (Gilead)
- Dolutegravir/Rilpivirine (Juluca) (ViiV/Johnson & Johnson)
- Cabotegravir (ViiV) (Long-acting injectable)
Market Share Dynamics:
- Biktarvy, a combination of bictegravir, emtricitabine, and tenofovir alafenamide, leads in US sales, surpassing Tivicay in some segments.
- Tivicay remains preferred for individual monotherapy and some fixed-dose combinations not yet overtaken by newer integrase inhibitors.
Pricing and Revenue Outlook
Current Pricing (2023):
- Brand name Tivicay (30-day supply): Approximately $3,150 retail.
- Wholesale Acquisition Cost (WAC): Estimated at $2,600 per 30-day dose [3].
Pricing Trends:
- Prices have declined slightly due to biosimilar entries and increased competition, but brand-name Navicitty maintains premium pricing.
- Fixed-dose combinations tend to command higher prices, with some formulations exceeding $10,000 annually per patient.
| Market Price Projections (2023–2028): |
Year |
Estimated Price (per 30-day supply) |
Notes |
| 2023 |
$3,150 |
Current market price |
| 2024 |
$3,000 – $3,200 |
Slight decrease due to pharmacist rebates, biosimilar pressure |
| 2025 |
$2,900 – $3,150 |
Continued market competition |
| 2026 |
$2,800 – $3,100 |
Adoption of generics for older formulations |
| 2027 |
$2,700 – $3,050 |
Market stabilization, patent expiration in some regions |
Note: These projections assume no immediate patent challenges or biosimilar entrants in the US but consider potential generics in overseas markets.
Patent and Regulatory Environment Impact
Patent Status:
- The key composition patent for Tivicay is set to expire in the US in 2028, with some formulations possibly expiring earlier due to secondary patents.
- Patent expirations generally lead to price erosion, with generics entering the market within 1-2 years thereafter.
Regulatory Developments:
- Pending patent litigations could extend exclusivity.
- Emerging long-acting injectables and novel formulations could shift demand over the next decade.
Market Risks and Opportunities
Risks:
- Entry of generics or biosimilars in the US could reduce prices by 50% or more within 2 years post-patent expiry.
- Competitive therapies demonstrate similar efficacy, which could restrict pricing power for Tivicay.
- Changes in HIV treatment guidelines and reimbursement policies can influence market share.
Opportunities:
- Expansion into pediatric and adolescent populations.
- Combination with other HIV drugs for fixed-dose formulations.
- Geographic expansion into emerging markets with growing HIV prevalence.
Key Takeaways
- Tivicay remains a dominant player in the HIV ARV space with around 40% of the INSTI segment in the US.
- US retail prices hover around $3,150/month, with slight downward trends expected due to increased competition.
- Patent expiration in 2028 signals potential for significant price erosion post-expiry.
- The broader HIV market sustains stable demand, with global revenues near $22 billion in 2023.
- Competition, patent expiry, and biosimilar dynamics will heavily influence future pricing and market share.
FAQs
1. When will generic versions of Tivicay likely enter the US market?
Patent expiration is set for 2028, after which generics may enter, leading to substantial price reductions.
2. What are the key competitors to Tivicay?
Biktarvy, Isentress, Juluca, and long-acting injectable formulations such as Cabotegravir.
3. How does the price of Tivicay compare to combination therapies?
Combination therapies like Biktarvy or Triumeq tend to have higher annual costs but can simplify regimens, which influences prescribing patterns.
4. How will pricing strategies adapt post-patent expiry?
Expect significant price discounts, with potential for generics reducing costs by 50% or more within two years of market entry.
5. What market factors could influence demand for Tivicay in the coming years?
Emergence of long-acting injectables, evolving treatment guidelines, patent litigations, and geographic expansion opportunities.
References
[1] IQVIA, 2022. US HIV market share data.
[2] EvaluatePharma, 2022. HIV drug market analysis.
[3] Red Book, 2023. Wholesale acquisition costs for HIV medications.
